Pharmaceutical Benefits Scheme
9 articles on Pharmaceutical Benefits Scheme, researched and written by the Shotlee Editorial Team from primary sources.
Mounjaro (Tirzepatide) PBS Listing Fails: Impact on Australian Patients
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
6 min read
Understanding the Mounjaro (Tirzepatide) PBS Standoff and What It Means for Patients
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
6 min read
What to Know If Taking Weight Loss Drugs Like Ozempic
Roughly half a million Australians are using GLP-1 weight loss drugs like Ozempic and Mounjaro, with some reporting life-changing results while others face side effects. Professor Kelly Lambert from the University of Wollongong shares key insights on what you need to know. This guide covers mechanisms, safety, and practical tips for users.
5 min read
Novo Nordisk Expands Ozempic, Wegovy Testing on Adolescents
Novo Nordisk, maker of Ozempic and Wegovy, has launched a three-year research partnership to test weight-loss GLP-1 drugs on adolescents in Pacific Island nations, beginning in Fiji. Announced amid a Danish royal visit, this move addresses the obesity 'ticking bomb' threatening kids' lifespans. CEO Mike Doustdar urges bolder action on prevention and access.
5 min read
Specialist: Funding Wegovy Saves Taxpayer Money Long-Term
Pharmac is evaluating funding for Wegovy, a GLP-1 receptor agonist, to combat New Zealand's high obesity rates. Weight loss specialist Dr. Gerard McQuinlan says it could save taxpayers billions by preventing diseases like Type 2 diabetes. Experts weigh long-term costs, side effects, and criteria.
2 min read
Pharmac Seeks Advice on Funding Wegovy Weight Loss Drug
New Zealand faces the third-highest adult obesity rate in the OECD, prompting Pharmac to seek clinical advice on funding Wegovy. Two applications propose semaglutide for high-BMI patients with cardiovascular risks or comorbidities. Experts argue it could save billions by preventing diseases like Type 2 diabetes.
2 min read
Health Minister Advances Wegovy's PBS Inclusion
The Australian government is set to partner with manufacturers to make Wegovy available on the Pharmaceutical Benefits Scheme for obesity management. This follows expert recommendations from the PBAC, addressing high private costs and equity in healthcare access.
2 min read
newsGP - Wegovy Suggested for PBS Inclusion
Semaglutide (Wegovy) is nearing PBS inclusion for adults with cardiovascular disease and obesity, following a PBAC recommendation. The recommendation identifies specific groups to prioritize for access to GLP-1 receptor agonist medicines.
2 min read
Ozempic's Impact: Reshaping Supermarkets and Stock Valuations
The rise in popularity of weight loss medications such as Ozempic and Mounjaro is significantly impacting both the food industry and the stock market. Eli Lilly, a pharmaceutical company, experienced a surge in valuation after reporting substantial sales increases. These drugs are changing eating patterns and redefining obesity treatment.
6 min read